Bastian Dehmel
Corporate Officer/Principal presso OCULIS HOLDING AG
Profilo
Bastian Dehmel is currently the Chief Development Officer at Oculis Holding AG.
Previously, he held the position of Executive Director-Global Medical Development at Amgen (Europe) GmbH from 2013 to 2017 and Chief Medical Officer at OxThera AB from 2017 to 2021.
Dr. Dehmel obtained a doctorate degree from Freie Universität Berlin.
Posizioni attive di Bastian Dehmel
| Società | Posizione | Inizio |
|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 01/01/2022 |
Precedenti posizioni note di Bastian Dehmel
| Società | Posizione | Fine |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Direttore Tecnico/Scientifico/R&S | 01/12/2021 |
| Amgen (Europe) GmbH | Corporate Officer/Principal | 01/07/2017 |
Formazione di Bastian Dehmel
| Freie Universität Berlin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| OCULIS HOLDING AG | Health Technology |
| Aziende private | 2 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
| Amgen (Europe) GmbH |
- Borsa valori
- Insiders
- Bastian Dehmel
